Fox Run Management, L.L.C. Adaptive Biotechnologies Corp Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$6.19 - $8.78 $8,511 - $12,072	1,375 Added 6.76%	21,724 $145,000
Q1 2023 May 12, 2023	BUY	$7.8 - $10.11 $8,767 - $11,363	1,124 Added 5.85%	20,349 $179,000
Q4 2022 Feb 07, 2023	BUY	$6.26 - $9.34 $120,348 - $179,561	19,225 New	19,225 $146,000
Q2 2022 Aug 12, 2022	SELL	$6.4 - $14.73 $92,742 - $213,452	-14,491 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$10.12 - $28.9 $146,648 - $418,789	14,491 New	14,491 $201,000
Q4 2021 Feb 09, 2022	SELL	$25.17 - $36.85 $224,315 - $328,407	-8,912 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$30.02 - $39.87 $267,538 - $355,321	8,912 New	8,912 $303,000

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.